{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:04:53Z","timestamp":1790787893997,"version":"4.1.0"},"reference-count":89,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The emergence of biologics with different modes of action (MoAs) and therapeutic targets has changed treatment patterns in patients with inflammatory rheumatic diseases. While tumour necrosis factor inhibitors (TNFis) are often utilized as the first biologic disease-modifying antirheumatic drug, some patients may not respond adequately (primary failure), fail to sustain response over time (secondary failure), or experience intolerable adverse events. Whether these patients would benefit more from cycling to a different TNFi or switching to a biologic with a different MoA is still unclear. We discuss here treatment outcomes of TNFi cycling versus MoA switching after treatment failure with a first TNFi in patients with inflammatory rheumatic diseases, focusing specifically on rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthritis. Treatment guidelines for these patients are ambiguous and, at times, contradictory in their recommendations. However, this is due to a lack of high-quality head-to-head data to definitively support cycling between TNFis after failure to a first-line TNFi over switching to a different MoA.<\/jats:p>","DOI":"10.1093\/mr\/road033","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T09:44:45Z","timestamp":1680774285000},"page":"11-26","source":"Crossref","is-referenced-by-count":16,"title":["Management of patients with inflammatory rheumatic diseases after treatment failure with a first tumour necrosis factor inhibitor: A narrative review"],"prefix":"10.1093","volume":"34","author":[{"given":"Roberto","family":"Caporali","sequence":"first","affiliation":[{"name":"Department of Clinical Science and Community Health, University of Milan , Milan, Italy"},{"name":"Department of Rheumatology, ASST Pini-CTO , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome , Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation (DETO), University of Bari, Section of Rheumatology , Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"2024061306563588000_R1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"New Engl J Med"},{"key":"2024061306563588000_R2","article-title":"Remicade (Infliximab) EPAR","author":"European Medicines Agency"},{"key":"2024061306563588000_R3","article-title":"Enbrel (Etanercept) EPAR","author":"European Medicines Agency"},{"key":"2024061306563588000_R4","article-title":"Humira (Adalimumab) EPAR","author":"European Medicines Agency"},{"key":"2024061306563588000_R5","article-title":"Simponi (Golimumab) EPAR","author":"European Medicines Agency"},{"key":"2024061306563588000_R6","article-title":"Cimzia (Certolizumab Pegol) EPAR","author":"European Medicines Agency"},{"key":"2024061306563588000_R7","article-title":"Tumor necrosis factor inhibitors","volume-title":"StatPearls","author":"Gerriets","year":"2022"},{"key":"2024061306563588000_R8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40265-022-01821-0","article-title":"Ozoralizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"2024061306563588000_R9","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1080\/21645515.2020.1836919","article-title":"Golimumab (anti-TNF monoclonal antibody): where we stand today","volume":"17","author":"Melo","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2024061306563588000_R10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/RHU.0000000000000229","article-title":"An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies","volume":"21","author":"Bandr\u00e9s Ciga","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"2024061306563588000_R11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241575","article-title":"Safety profile of biologic drugs for psoriasis in clinical practice: an Italian prospective pharmacovigilance study","volume":"15","author":"Iannone","year":"2020","journal-title":"PLoS One"},{"key":"2024061306563588000_R12","article-title":"The risk of adverse effects of TNF-\u03b1 inhibitors in patients with rheumatoid arthritis: a network meta-analysis","volume":"13","author":"He","year":"2022","journal-title":"Front Immunol"},{"key":"2024061306563588000_R13","article-title":"Risk of adverse events after anti-TNF treatment for inflammatory rheumatological disease. A meta-analysis","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"2024061306563588000_R14","first-page":"S128","article-title":"Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis","volume":"20","author":"Gibofsky","year":"2014","journal-title":"Am J Manag Care"},{"key":"2024061306563588000_R15","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2024061306563588000_R16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024061306563588000_R17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024061306563588000_R18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024061306563588000_R19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3899\/jrheum.190299","article-title":"Comparative persistence of methotrexate and tumor necrosis factor inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"47","author":"George","year":"2020","journal-title":"J Rheumatol"},{"key":"2024061306563588000_R20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40744-020-00211-w","article-title":"Biologic disease-modifying antirheumatic drug prescription patterns among rheumatologists in Europe and Japan","volume":"7","author":"Sullivan","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2024061306563588000_R21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40744-020-00203-w","article-title":"Biologic disease-modifying antirheumatic drug prescription patterns for rheumatoid arthritis among United States physicians","volume":"7","author":"Sullivan","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2024061306563588000_R22","doi-asserted-by":"crossref","first-page":"vii42","DOI":"10.1093\/rheumatology\/key195","article-title":"Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus","volume":"57","author":"Todoerti","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2024061306563588000_R23","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211060910","article-title":"Comparison of long-term efficacy between biological agents following tumor necrosis factor inhibitor failure in patients with rheumatoid arthritis: a prospective cohort study","volume":"13","author":"Bogas","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024061306563588000_R24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/25785826.2020.1757920","article-title":"Non-TNF inhibitor switchers versus TNF inhibitor cyclers from multicentre rheumatoid arthritis ultrasonography prospective cohort in Japan","volume":"43","author":"Endo","year":"2020","journal-title":"Immunol Med"},{"key":"2024061306563588000_R25","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221091450","article-title":"Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure","volume":"14","author":"Park","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024061306563588000_R26","first-page":"192","article-title":"Treatment persistence and healthcare costs among patients with rheumatoid arthritis after a change in targeted therapy","volume":"11","author":"Bonafede","year":"2018","journal-title":"Am Health Drug Benefits"},{"key":"2024061306563588000_R27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03009742.2021.2003033","article-title":"Persistence of bDMARD therapy in rheumatoid arthritis after first-line TNF-inhibitor failure: the RECORD study of the Italian Society for Rheumatology","volume":"51","author":"Carrara","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"2024061306563588000_R28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/13696998.2016.1275653","article-title":"Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis","volume":"20","author":"Chastek","year":"2017","journal-title":"J Med Econ"},{"key":"2024061306563588000_R29","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/acr.24358","article-title":"Treatment sequences after discontinuing a tumor necrosis factor inhibitor in patients with rheumatoid arthritis: a comparison of cycling versus swapping strategies","volume":"73","author":"Karpes Matusevich","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024061306563588000_R30","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-017-1684-0","article-title":"Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis","volume":"18","author":"Wilke","year":"2017","journal-title":"BMC Musculoskelet Disord"},{"key":"2024061306563588000_R31","first-page":"103","article-title":"Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor","volume":"44","author":"Santos-Faria","year":"2019","journal-title":"Acta Reumatol Port"},{"key":"2024061306563588000_R32","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s12325-017-0578-8","article-title":"Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy","volume":"34","author":"Wei","year":"2017","journal-title":"Adv Ther"},{"key":"2024061306563588000_R33","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211002682","article-title":"Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis","volume":"13","author":"Migliore","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024061306563588000_R34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/acr2.11337","article-title":"TNFi cycling versus changing mechanism of action in TNFi-experienced patients: result of the Corrona CERTAIN comparative effectiveness study","volume":"4","author":"Curtis","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2024061306563588000_R35","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/1756-185X.13199","article-title":"Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry","volume":"21","author":"Favalli","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2024061306563588000_R36","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10067-022-06116-z","article-title":"Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry","volume":"41","author":"Tesser","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2024061306563588000_R37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2020.07.011","article-title":"Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA","volume":"88","author":"Iannone","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2024061306563588000_R38","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/rheumatology\/kem091","article-title":"Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice","volume":"46","author":"Bombardieri","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2024061306563588000_R39","first-page":"540","article-title":"Outcome in patients with rheumatoid arthritis switching TNF-alpha antagonists: a single center, observational study over an 8-year period","volume":"27","author":"Conti","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2024061306563588000_R40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2006.058776","article-title":"Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects","volume":"66","author":"Iannone","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2024061306563588000_R41","first-page":"1","article-title":"Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT","volume":"22","author":"Brown","year":"2018","journal-title":"Health Technol Assess"},{"key":"2024061306563588000_R42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/rheumatology\/keu237","article-title":"Psoriatic arthritis: current therapy and future approaches","volume":"54","author":"Huynh","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2024061306563588000_R43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2024061306563588000_R44","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024061306563588000_R45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024061306563588000_R46","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000880","article-title":"Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-na\u00efve and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry","volume":"5","author":"Mease","year":"2019","journal-title":"RMD Open"},{"key":"2024061306563588000_R47","article-title":"Long-term effectiveness of tumour necrosis factor-\u03b1 inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study","volume":"2","author":"Clunie","year":"2018","journal-title":"Rheumatol Adv Pract"},{"key":"2024061306563588000_R48","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3899\/jrheum.181272","article-title":"Real-world long-term effectiveness of tumor necrosis factor inhibitors in psoriatic arthritis patients from the Rheumatic Diseases Portuguese Register","volume":"47","author":"Vieira-Sousa","year":"2020","journal-title":"J Rheumatol"},{"key":"2024061306563588000_R49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3899\/jrheum.150744","article-title":"Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from Southern Sweden","volume":"43","author":"Kristensen","year":"2016","journal-title":"J Rheumatol"},{"key":"2024061306563588000_R50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00296-019-04416-3","article-title":"Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort","volume":"40","author":"Favalli","year":"2020","journal-title":"Rheumatol Int"},{"key":"2024061306563588000_R51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40744-019-0158-2","article-title":"Economic burden of switching to different biologic therapies among tumor necrosis factor inhibitor-experienced patients with psoriatic arthritis","volume":"6","author":"Song","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2024061306563588000_R52","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10067-018-3989-2","article-title":"Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the BIOlogic aPUlian REgistry (BIOPURE)","volume":"37","author":"Iannone","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2024061306563588000_R53","first-page":"581","article-title":"Efficacy and safety of ixekizumab in psoriatic arthritis: a retrospective, single-centre, observational study in a real-life clinical setting","volume":"38","author":"Manfreda","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2024061306563588000_R54","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/bjd.17837","article-title":"Relapse of psoriatic arthritis in patients with active psoriasis switched from tumour necrosis factor-\u03b1 to interleukin-17A inhibitor","volume":"181","author":"Gisondi","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024061306563588000_R55","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1093\/rheumatology\/keaa449","article-title":"Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis","volume":"59","author":"Xu","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024061306563588000_R56","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"2024061306563588000_R57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024061306563588000_R58","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024061306563588000_R59","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024061306563588000_R60","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40744-018-0129-z","article-title":"Tumor necrosis factor inhibitor discontinuation in patients with ankylosing spondylitis: an observational study from the US-based Corrona registry","volume":"5","author":"Mease","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2024061306563588000_R61","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.semarthrit.2017.04.005","article-title":"Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis","volume":"47","author":"Deodhar","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2024061306563588000_R62","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1908-9","article-title":"Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice","volume":"21","author":"Lindstr\u00f6m","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024061306563588000_R63","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000524","article-title":"Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review","volume":"3","author":"Navarro-Comp\u00e1n","year":"2017","journal-title":"RMD Open"},{"key":"2024061306563588000_R64","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jbspin.2019.07.003","article-title":"Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: a real-life multicenter study","volume":"86","author":"Krajewski","year":"2019","journal-title":"Joint Bone Spine"},{"key":"2024061306563588000_R65","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1111\/1756-185X.13375","article-title":"Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)","volume":"21","author":"Soubrier","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2024061306563588000_R66","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1093\/rheumatology\/keab245","article-title":"Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure","volume":"60","author":"Min","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024061306563588000_R67","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1136\/annrheumdis-2019-215934","article-title":"Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort","volume":"79","author":"Micheroli","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024061306563588000_R68","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2024061306563588000_R69","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward NEW CLASSIFICATION CRITERIA FOR JUVENILE IDIOPATHIC ARTHRITIS: FIRST STEPS, Pediatric Rheumatology International Trials Organization International Consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"2024061306563588000_R70","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/acr.23871","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis","volume":"71","author":"Angeles-Han","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024061306563588000_R71","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American College of Rheumatology Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024061306563588000_R72","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40884","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024061306563588000_R73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1573403X16999200917151805","article-title":"Current therapeutic options for the treatment of juvenile idiopathic arthritis","volume":"17","author":"Saougou","year":"2021","journal-title":"Curr Rheumatol Rev"},{"key":"2024061306563588000_R74","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2147\/OPTH.S342717","article-title":"Management strategies of juvenile idiopathic arthritis-associated chronic anterior uveitis: current perspectives","volume":"16","author":"Paroli","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"2024061306563588000_R75","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3899\/jrheum.200437","article-title":"Biologic switching among nonsystemic juvenile idiopathic arthritis patients: a cohort study in the Childhood Arthritis and Rheumatology Research Alliance Registry","volume":"48","author":"Mannion","year":"2021","journal-title":"J Rheumatol"},{"key":"2024061306563588000_R76","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2665-9913(20)30025-4","article-title":"Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study","volume":"2","author":"Kearsley-Fleet","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2024061306563588000_R77","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-021-00630-1","article-title":"Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab","volume":"19","author":"Lanz","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"2024061306563588000_R78","doi-asserted-by":"crossref","first-page":"620","DOI":"10.55563\/clinexprheumatol\/1u8y08","article-title":"Secukinumab in the treatment for patients with juvenile enthesitis related arthritis non-responsive to anti-TNF treatment according the Juvenile Spondyloarthritis Disease Activity Index","volume":"40","author":"Baer","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2024061306563588000_R79","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/rheumatology\/keab460","article-title":"Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg\/ml): 52-week randomized, double-blind study in rheumatoid arthritis","volume":"61","author":"Furst","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2024061306563588000_R80","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1910-2","article-title":"Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024061306563588000_R81","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/14397595.2021.1899591","article-title":"Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024061306563588000_R82","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11030621","article-title":"Efficacy and drug survival after switching from etanercept to the biosimilar SB4: a real-life long-term study","volume":"11","author":"Parisi","year":"2022","journal-title":"J Clin Med"},{"key":"2024061306563588000_R83","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/03007995.2021.1923467","article-title":"A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-na\u00efve patients and in patients undergoing non-medical switch from originator","volume":"37","author":"Giunta","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"2024061306563588000_R84","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/rheumatology\/keab572","article-title":"OBSIDIAN - real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis","volume":"61","author":"Maccora","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2024061306563588000_R85","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/acr2.11325","article-title":"Efficacy and safety of etanercept biosimilars compared with the originator for treatment of juvenile arthritis: a prospective observational study","volume":"3","author":"Thiele","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"2024061306563588000_R86","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/ncprheum0438","article-title":"Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?","volume":"3","author":"Rigby","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2024061306563588000_R87","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12325-021-01879-4","article-title":"Treatment persistence in patients cycling on subcutaneous tumor necrosis factor-alpha inhibitors in inflammatory arthritis: a retrospective study","volume":"39","author":"Dal\u00e9n","year":"2022","journal-title":"Adv Ther"},{"key":"2024061306563588000_R88","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40261-019-00782-9","article-title":"Effectiveness of certolizumab-pegol in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis based on the BIOPURE registry: can early response predict late outcomes?","volume":"39","author":"Iannone","year":"2019","journal-title":"Clin Drug Investig"},{"key":"2024061306563588000_R89","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s12325-022-02064-x","article-title":"Treatment failure in axial spondyloarthritis: insights for a standardized definition","volume":"39","author":"Juanola","year":"2022","journal-title":"Adv Ther"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/road033\/54151755\/road033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/1\/11\/58214261\/road033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/1\/11\/58214261\/road033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T06:24:23Z","timestamp":1718259863000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/1\/11\/7109864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,4,6]]},"published-print":{"date-parts":[[2023,12,22]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/road033","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,4,6]]}}}